Padakonn Pharma OÜ
Anti-MBG antibodies for CKD fibrosis and preeclampsia
Targeting Marinobufagenin to advance renal, vascular and pregnancy-related disease research.
↗
Platform video
Company focus
A focused biotech platform for MBG neutralization.
Padakonn Pharma OÜ connects Marinobufagenin biology, CKD fibrosis research and dialysis-compatible antibody immobilization.
4 clones
anti-MBG antibodies
OÜ
Estonian biotech
Keywords
Search themes around MBG and fibrosis.
marinobufagenin anti-MBG antibody CKD fibrosis Na+/K+-ATPase vascular stiffness MBG biomarker immunoadsorption preeclampsia
Product platform
Blocking circulating MBG before fibrosis advances.
Padakonn is developing antibody-bound filters intended to neutralize Marinobufagenin in blood circulation and support future extracorporeal therapy workflows.
Anti-MBG monoclonal antibody clones
Antibody immobilization on HiTrap NHS-Activated media
Extracorporeal MBG neutralization concept
Dialysis-adjacent compatibility target
Research
MBG, fibrosis and vascular dysfunction.
Research themes for nephrology, dialysis cardiovascular risk and preeclampsia-related vascular complications.
MBG biology
Endogenous cardiotonic steroids
Padakonn targets Marinobufagenin, an endogenous cardiotonic steroid associated with Na+/K+-ATPase signaling, collagen synthesis and vascular fibrosis.
CKD axis
Fibrosis and vascular stiffness
The research focus links CKD progression, dialysis-stage cardiovascular risk, renal fibrosis and vascular remodeling biomarkers.
Translation
Preeclampsia and vascular disease
Shared MBG-driven vascular dysfunction creates a translational path across nephrology, hypertension and pregnancy-related vascular complications.
Clinical questions
How the platform is positioned.
Why MBG?
Elevated MBG is connected with sodium pump inhibition, profibrotic signaling and vascular stiffness in renal and cardiovascular disease models.
Why extracorporeal?
A filter-based approach is designed to neutralize circulating MBG outside the body and align with infrastructure already familiar to renal care.
Why now?
The field needs targeted approaches for CKD-associated fibrosis, dialysis cardiovascular risk and pregnancy-related vascular dysfunction.
Scientific keywords
A focused language map for clinicians, researchers and partners.
The core vocabulary follows the biology: MBG, CKD fibrosis, sodium pump signaling, vascular stiffness and extracorporeal neutralization.
MBG science
marinobufageninendogenous cardiotonic steroidsMBG signaling pathwayFli1 signalingcollagen-1 signaling
Nephrology
chronic kidney diseaseCKD fibrosisrenal fibrosishemodialysis technologyvascular stiffness in CKD
Therapeutics
anti-MBG monoclonal antibodyMBG immunoadsorptionfibrosis targeted therapyprecision nephrologyextracorporeal therapy
Clinical signals
MBG biomarkerpreeclampsia biomarkerendothelial dysfunctionhypertension signalingvascular remodeling
Team
Scientific and clinical leadership.
A cross-border team combining nephrology, clinical research, antibody biology and business development.
Alexei Bagrov, MD, PhD
Principal Investigator, Co-founder
Estonia
David Adair, MD, PhD
Product Developer
USA
Olle Melander, MD, PhD
Researcher, R&D
Sweden
Mai Rosenberg, MD, PhD
Chief Clinical, Researcher
Estonia
Kirill Smirnov, MBA
Chief Business Officer, Co-founder
Estonia
Evidence base
Selected literature
Publications supporting the MBG, fibrosis and cardiovascular-risk thesis behind the platform.
- Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets. Pharmacol Rev. 2009. Source
- Endogenous cardiotonic steroids in chronic renal failure. Nephrol Dial Transplant. 2011. Source
- Antibody to Marinobufagenin reverses placenta-induced fibrosis of umbilical arteries in preeclampsia. Int J Mol Sci. 2018. Source
- Marinobufagenin-induced vascular fibrosis is a likely target for mineralocorticoid antagonists. J Hypertens. 2015. Source
- Antibody to endogenous cardiotonic steroid reverses vascular fibrosis and restores vasorelaxation in chronic kidney disease. Int J Mol Sci. 2024. Source
Inquiry
Start a focused conversation with Padakonn Pharma.
For investment research, scientific questions, translational partnerships, product diligence and media requests.
We route inquiries by topic and reply from the relevant team member.
For investor or partner materials, include your organization and the context of your request.